A biotechnology company looking to alleviate a problem in cell and gene therapy production emerged from “stealth” mode on Tuesday, unveiling itself alongside $64 million in funding.
Based in Philadelphia, VintaBio was founded by Junwei Sun and Shangzhen Zhou, two well-known researchers at the University of Pennsylvania. Both founders have been instrumental to the development of viral vectors — essential tools used to ship helpful genetic material into cells — that were part of cell and gene therapy treatments now on the market.
